A Chicago-based center that has long operated a clinical trial program for stem cell therapies, has stopped recruiting further patients as its chief, Richard Burt, leaves for a research sabbatical.

The researchers aim to grow transplantable human organs from primate embryos.

So far, the only evidence that treatments like this one work is anecdotal.

Two coauthors of a new study discuss their findings about nearly 170 facilities in the southwestern US selling unproven therapies—and what should be done about them.

Researchers track which genes are active in the polyp during successive cell states.

Human embryonic stem cells differentiate and organize themselves on a chip.

The research may necessitate the formation of new ethical guidelines.

The decision may facilitate the agency cracking down more effectively on the unproven interventions these companies sell.

The cells, derived from induced pluripotent stem cells, are in testing as an immunotherapy for cancer patients with solid tumors.